A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

Inclusion Criteria: * Male or female participants, between 18 and 75 years of age, inclusive * 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; normal QT interval confirmed * Contraception (with double contraception methods) for male and female (unless postmenopausal) participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants. * Having given written informed consent prior to any procedure related to the study * Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research * Not under any administrative or legal supervision Participants with HI * Body weight between 50.0 and 125.0 kg, inclusive if male, and between 40.0 and 110.0 kg, inclusive if female, body mass index (BMI) between 18.00 and 34.99 kg/m2, inclusive * Stable chronic liver disease assessed by medical history, physical examination, laboratory values * Vital signs after 10 minutes resting in supine position within the following range \[or if out of range, considered not clinically significant (NCS) by the Investigator\]: * 95 mmHg \< systolic blood pressure (SBP) \< 180 mmHg * 45 mmHg \< diastolic blood pressure (DBP) \< 100 mmHg * 40 bpm \< HR \< 100 bpm * Laboratory parameters within the acceptable range for participants with HI; however, serum creatinine should be strictly below the upper laboratory normal * …